건선 및 건선관절염 환자에서 생물학적 제제 사용을 위한 선별 검사 = The Screening Tests for biologics use in psoriasis and psoriatic arthritis patients

다국어 초록 (Multilingual Abstract)

Psoriasis and psoriasis arthritis are chronic progressive inflammatory diseases with significant comorbidities including autoimmune conditions, cardiovascular diseases, depressive disorder as well as life quality impairment. The purpose of treatment for psoriasis is to improve psoriatic lesions without severe adverse events and prevent long-term recurrence.
Since 2002, biologic agent has been introduced as a treatment method for psoriasis and there have been a lot of studies on the safety and efficacy of the biologic agents. In particular, the biologic agents for moderate to severe psoriasis have been widely used. This article is intended to provide a review of the literatures on screening tests for biologic agents in patients with psoriasis and psoriatic arthritis

참고문헌 (Reference)

1 Frankel AJ, "Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation" 61 : 1044-1055, 2009

2 Ahn CS, "To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis" 73 : 420-428 e421, 2015

3 Nakahara T, "Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab" 2018

4 Hai-Jin Park, "The subsidy Program of national Health Insurance Service for severe Psoriasis Patients" 14 : 27-30, 2017

5 Chiu HY, "The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C" 169 : 1295-1303, 2013

6 Young L, "The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis" 53 : 57-60, 2012

7 Domm S, "The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections:a review of the literature" 159 : 1217-1228, 2008

8 Boehncke WH, "The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity" 20 : 303-307, 2011

9 Maya Y, "Severe subcutaneous hematoma in a patient with psoriatic arthritis:Changes of platelet count in psoriatic patients with biologic agents" 44 : 1385-1388, 2017

10 Warren RB, "Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database" 179 : 1205-1207, 2018

11 Martinez-Lopez A, "Screening for Latent Tuberculosis in the Patient With Moderate to Severe Psoriasis Who Is a Candidate for Systemic and/or Biologic Therapy" 107 : 207-214, 2016

12 Kamata M, "Safety of biologics in psoriasis" 45 : 279-286, 2018

13 Navarro R, "Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting" 168 : 609-616, 2013

14 Chiu HY, "Safety Pro fi le of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study" 98 : 829-834, 2018

15 Kaushik SB, "Review of safety and efficacy of approved systemic psoriasis therapies" 2018

16 Van Lumig PP, "Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab" 165 : 375-382, 2011

17 Abramson A, "Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management" 67 : 1349-1361, 2012

18 Doherty SD, "National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents" 59 : 209-217, 2008

19 Strober BE, "Monitoring Biologic Therapy in Psoriasis: A Primer" 2016

20 Gisondi P, "Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry" 27 : e30-e41, 2013

21 Langley RG, "Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: An integrated analysis from 11 clinical trials" 2018

22 Gordon K, "Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL" 66 : 241-251, 2012

23 Joint Committe for the Revision of Korean Guidelines for Tuberculosis KCFDCaP, "Korean guidelines for Tuberculosis"

24 Ohtsuki M, "Japanese guidance for use of biologics for psoriasis (the 2013 version)" 40 : 683-695, 2013

25 우광숙, "Interferon-gamma Release Assay의 임상적 이용" 대한진단검사의학회 6 (6): 8-11, 2016

26 Kammuller M, "Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections" 6 : e152-, 2017

27 Malvern P, "Infliximab (Remicade) [package insert]"

28 Kaine J, "Higher Incidence Rates of Comorbidities in Patients with Psoriatic Arthritis Compared with the General Population Using U.S. Administrative Claims Data" 1-11, 2018

29 Perez-Alvarez R, "Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases" 90 : 359-371, 2011

30 Lebwohl M, "From the Medical Board of the National Psoriasis Foundation:monitoring and vaccinations in patients treated with biologics for psoriasis" 58 : 94-105, 2008

31 Hugh J, "From the Medical Board of the National Psoriasis Foundation:The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies" 70 : 168-177, 2014

32 Motaparthi K, "From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factoralfa inhibitors or other immunosuppressive agents in patients with psoriasis" 70 : 178-186, 2014

33 Han JH, "Epidemiology and Medication Trends in Patients with Psoriasis: A Nationwide Population-based Cohort Study from Korea" 98 : 396-400, 2018

34 Smith CH, "British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009" 161 : 987-1019, 2009

35 Schadler ED, "Biologics for the primary care physician:Review and treatment of psoriasis" 2018

36 Sivamani RK, "Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring" 44 : 121-140, 2013

37 Carter JD, "A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database" 36 : 635-641, 2009